Taurel predicts flat Zyprexa sales
Safety jitters will cause sales of Eli Lilly and Co.’s Zyprexa schizophrenia drug to stop growing this year and stabilize at 2006 levels, CEO Sidney Taurel told reporters yesterday following a meeting at the Chief Executive’s Club at Boston College. The blockbuster drug has been blamed for weight gain and triggering diabetes in some patients. […]